Audio By Carbonatix
An American biotech company says it created a coronavirus vaccine three hours after getting access to the virus' genetic sequence in mid-January, and now scientists are racing to get the vaccine on the market in record time.
Inovio Pharmaceuticals is based in Pennsylvania, but scientists in its laboratory in San Diego made the discovery.
"We were able to rapidly construct our vaccine in a matter of about three hours once we had the DNA sequence from the virus available because of the power of our DNA medicine platform," Dr. J. Joseph Kim, Inovio's president and CEO, told FOX Business. "Our goal is to start phase one human testing in the U.S. early this summer."
China has reported 254 new daily deaths and a spike in new daily virus cases of 15,152, after new methodology was applied in the hardest-hit province of Hubei as to how cases are categorised.
Medical workers treat patients in the isolated intensive care unit at a hospital in Wuhan in central China's Hubei province Thursday.
Inovio's stock jumped to $5.32 a share a few days after the company announced it was selected to work on a coronavirus vaccine.
The American company is partnering with Beijing Advaccine, a Chinese company, to work on the vaccine. Inovio also received $9 million to work on the vaccine from the Coalition for Epidemic Preparedness Innovations, which is backed by billionaire Bill Gates.
"We’ve done this many, many times before. The most relevant was building our vaccine against MERS virus, which is a coronavirus in the same family as COVID-19," Kim said.
Inovio took a vaccine for Zika virus from construct design to human testing in the U.S. in less than seven months, Kim said.
"We’re planning to beat our own record," he said. "Maybe we could do that in close to half that time."
Inovio is building a coalition for the "war" against COVID-19 that will require scaling up to thousands upon thousands of doses, Kim said.
Another U.S. company, Maryland-based Novavax, is aiming to make a coronavirus vaccine in as little as three months, although such vaccines can take years to develop. The company made an Ebola vaccine in 90 days.
Medical workers treat patients in the isolated intensive care unit at a hospital in Wuhan in central China's Hubei province Thursday.
Inovio's stock jumped to $5.32 a share a few days after the company announced it was selected to work on a coronavirus vaccine.
The American company is partnering with Beijing Advaccine, a Chinese company, to work on the vaccine. Inovio also received $9 million to work on the vaccine from the Coalition for Epidemic Preparedness Innovations, which is backed by billionaire Bill Gates.
"We’ve done this many, many times before. The most relevant was building our vaccine against MERS virus, which is a coronavirus in the same family as COVID-19," Kim said.
Inovio took a vaccine for Zika virus from construct design to human testing in the U.S. in less than seven months, Kim said.
"We’re planning to beat our own record," he said. "Maybe we could do that in close to half that time."
Inovio is building a coalition for the "war" against COVID-19 that will require scaling up to thousands upon thousands of doses, Kim said.
Another U.S. company, Maryland-based Novavax, is aiming to make a coronavirus vaccine in as little as three months, although such vaccines can take years to develop. The company made an Ebola vaccine in 90 days.DISCLAIMER: The Views, Comments, Opinions, Contributions and Statements made by Readers and Contributors on this platform do not necessarily represent the views or policy of Multimedia Group Limited.
DISCLAIMER: The Views, Comments, Opinions, Contributions and Statements made by Readers and Contributors on this platform do not necessarily represent the views or policy of Multimedia Group Limited.
Latest Stories
-
Constitution Review Committee submits final report to President Mahama
5 minutes -
41 arrested in targeted police operations across Eastern Region
21 minutes -
Supreme Court affirms Alpha Beta Education Centre’s title to Akokorfoto lands
39 minutes -
Constitutional Review Committee proposes 5-year presidential term
46 minutes -
Biomedical engineers shortage threatens Ghana’s medical diagnostics – GSBE President
52 minutes -
Crypto currency influencers to face sanctions without SEC, BoG authorisation
53 minutes -
Strategic Tourism Diplomacy: How Ghana can achieve annual growth through global best practices
55 minutes -
The quiet Christmas we rarely talk about
58 minutes -
Police arrest three individuals for impersonating public officials and online fraud
1 hour -
Ghana’s Golden Opportunity: Building a world-class labour export system
1 hour -
CILAGÂ inducts new executives, marks decade of excellence with Festival of Nine Lessons & Carols
2 hours -
Rev. Wengam condemns abuse of power, urges moral leadership at festival of Nine Lessons and Carols
2 hours -
Ghana ends year at 23rd position in Africa with highest fuel prices
2 hours -
DJ Bridash cements place among Ghana’s leading radio DJs
2 hours -
MFWA criticises court order blocking investigative journalist’s publications
2 hours
